Healthcare ❯ Pharmaceutical Industry

Drug Development

Clinical Trials Research and Development Market Trends GLP-1 Medications Obesity Treatments Efficacy Studies Weight Loss Medications FDA Approval Cancer Drugs Innovation Monoclonal Antibodies Research Funding ALS Treatment Regulatory Approval Mental Health Treatments Cancer Therapies Cancer Medicines Pricing Strategies Antiviral Drugs Immunological Treatments AI in Healthcare Weight Management Drugs Pricing Policies Market Strategy Weight Loss Drugs Biologics Long-Acting Injectables Biopharmaceuticals Obesity Treatment Diabetes Treatment Market Competition Market Access Clinical Efficacy Antibiotics Covid-19 Vaccines Regulatory Compliance Cancer Treatments

Eli Lilly Picks Huntsville for $6 Billion API Plant to Supply Next-Gen Drugs

The move advances onshoring of active ingredients to support orforglipron within Lilly’s $27 billion U.S. buildout.

Pfizer Closes Metsera Buyout, Adding GLP-1 Assets in Cash-Plus-CVR Deal

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

Teva’s Olanzapine LAI Shows No PDSS in Phase 3 SOLARIS Long-Term Data Presented at Psych Congress

AstraZeneca H1 Revenue Jumps 11% as It Pledges $50 Billion U.S. Expansion

AstraZeneca Commits $50 Billion to U.S. Manufacturing and Research by 2030